Intraoperative frozen section analysis of ovarian tumors: a 11-year review of accuracy with clinicopathological correlation in a Hong Kong Regional hospital

Fred Yau-Lung Kung, Alex Koon-ho Tsang, Ellen Lok-man Yu

ABSTRACT

Objective Intra-operative frozen section (IFS) can provide an instinct guide for treatment of ovarian tumors intra-operatively, though limitations exist. This study intended to evaluate the diagnostic performance of IFS and possible clinicopathological factors influencing the diagnostic accuracy of IFS.

Methods A retrospective review of IFS of ovarian lesions from 2006 to 2016 was done. The diagnostic performance of benign, borderline, and malignant IFS diagnosis was evaluated. Logistic regression analysis was used to assess the influence of clinicopathological parameters on the likelihood of underdiagnosis.

Results There were 1143 consecutive cases during the study period. The overall accuracy was 93.7%. For benign diagnoses, the IFS diagnostic accuracy, sensitivity, and specificity were 97.20%, 100%, and 92.51%, respectively. If borderline and malignant diagnoses were considered as a single group, the IFS diagnostic accuracy was 97.20%, with 92.51% sensitivity and 100% specificity. At univariate regression analysis, intact capsules at time of delivery (ORunadj = 1.9), stage I lesions (ORunadj = 3.76) and ultrasound (USG) score 0 (ORunadj = 2.52) were positively associated with underdiagnosis. Further multivariate analysis showed that only stage I lesions (OR = 3.62) and USG score 0 (OR = 2.32) were positively associated with underdiagnosis. For the cases with underdiagnosed IFS, 54% (34/63) received incomplete primary staging surgery.

Conclusions The study demonstrated that IFS provided excellent specificity to differentiate borderline or malignant tumors from benign lesions. IFS in early-stage ovarian cancers needs to be interpreted with caution, though IFS is most important for this group of lesions. A reliable IFS diagnosis often requires efficient communication between surgeons and pathologists.

INTRODUCTION

Intra-operative frozen section (IFS) as an intra-operative diagnostic tool to guide procedural decision has been used for more than 100 years, since Louis B. Wilson published his technique in a JAMA article dated December 1905. In gynecological oncology, the most common scenario requiring IFS is probably in the evaluation of ovarian masses. Risk of Malignancy Index (RMI) has been used in many national guidelines to predict malignant risk of ovarian masses. Newer models, such as the Assessment of Different NEoplasias in the adnexa (ADNEX) model, perform better than RMI. However, gynecologists may still encounter unexpected ovarian masses intra-operatively that are of unknown nature or suspicious of malignancy. An accurate IFS can provide a reliable guide, thus minimizing the chance of overtreatment with unnecessary procedures or undertreatment requiring a second operation or adjuvant chemotherapy. A recent systematic review has concluded that IFS has an average sensitivity of 90% and specificity of 99.5% in diagnosing ovarian malignancy. It is well known that IFS has its limitations, such as in the diagnosis of borderline and mucinous ovarian tumors. Although a survey in the United Kingdom found that IFS is less commonly performed, in many countries this practice is still considered routine in most cases.

In this study, we assessed the accuracy of IFS as a diagnostic test for benign, borderline, and malignant ovarian tumors in a regional hospital in Hong Kong. Possible clinicopathological factors affecting the diagnostic accuracy of IFS were investigated.

METHODS

A retrospective review of IFS of ovarian lesions from January 2006 to December 2016 was done at a regional hospital in Hong Kong. All consecutive cases of ovarian lesions with IFS done in the studied period were retrieved from the electronic histopathology database, using systematized nomenclature of medicine codes (SNOMED). The histopathology reports, medical records, and operation notes were reviewed in the Clinical Management System (CMS). Medical records were further retrieved from the Medical Records Office for review of ultrasound (USG) images of tumors (if not well documented in the electronic records). Retrieved data included age of the patients, menopausal status, tumor histology, FIGO (International Federation of Gynecology and Obstetrics) staging, tumor capsule integrity at time of tumor excision, number of IFS tissue blocks required, whether imprints were performed or not, tumor size...
RESULTS

The cohort included 1149 ovarian lesions sent for IFS reporting from January 2006 to December 2016. Six cases were excluded as the diagnosis was deferred from the time of the IFS (0.5%). The final study cohort comprised 1143 cases, with 716 benign, 133 borderline, and 294 malignant. Table 1 shows the comparison of IFS and paraffin section diagnoses. There were 1071 concordant and 72 discordant cases. The overall accuracy was 93.7%. All IFS and paraffin slides of discordant cases were reviewed and confirmed. Seventy cases (97%) of the discordant cases were underdiagnosed at IFS, with only two cases (3%) of overdiagnosis, resulting in an overall underdiagnosis rate of 6.1% and an overall overdiagnosis rate of 0.2%. No benign lesion was overdagnosed as borderline or malignant in IFS. Table 2 shows the diagnostic values of benign, borderline, and malignant IFS diagnoses, respectively. For benign diagnoses, the IFS diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with 95% CI were 97.20%, 95.19%, 95.01%, 95.20%, and 100%, respectively.

Table 2 Diagnostic value of frozen section for benign, borderline, and malignant lesions (N=1143)

| Diagnostic value (%) (95% CI) | Benign | Borderline | Malignant | Borderline/malignant |
|-------------------------------|--------|------------|-----------|----------------------|
| Accuracy                     | 97.20  | 95.19      | 95.01     | 97.20                |
| Sensitivity                   | 100    | 97.22      | 81.29     | 92.51                |
| Specificity                   | 92.51  | 96.24      | 99.76     | 100                   |
| Positive predictive value     | 95.72  | 75.32      | 99.17     | 100                   |
| Negative predictive value     | 100    | 98.28      | 93.90     | 95.72                |

Kung FY-L, et al. Int J Gynecol Cancer 2019;29:772–778. doi:10.1136/ijgc-2018-000048
sensitivity, and specificity were 95.19%, 87.22%, and 96.24%, respectively. For malignant diagnoses, the IFS diagnostic accuracy, sensitivity, and specificity were 97.20%, 81.29%, and 99.76%, respectively. If borderline and malignant diagnoses were considered as a single group, the IFS diagnostic accuracy increased to 97.20%, with 92.51% sensitivity and 100% specificity.

There were 427 cases with final pathology of either borderline or malignant for logistic regression in the current study. As there were only two cases with overdiagnosis, this group was not further analyzed for lack of statistical power. Finally 425 cases remained for subsequent logistic regression. Pearson’s χ² test or Fisher’s exact test were performed to compare the correct diagnosis and underdiagnosis groups. Table 3 shows the clinicopathological characteristics of the cases of borderline and malignant lesions, and whether the cases had correct diagnosis, underdiagnosis, or overdiagnosis. The mean age of the study population was 49.83 (13–91) years, with 79.4% (338/427) aged 40+ years, and 46.4% (198/427) were post-menopausal. Epithelial tumors accounted for 79.6% of cases, including 15.7% (67/427) serous tumors, 29.0% (124/427) mucinous tumors, 17.1% (73/427) endometrioid tumors, and 17.6% (76/427) clear cell tumors. Almost 70% (299/427) of cases were stage I. The mean ovarian tumor diameter was 14.5 cm (2–40 cm), and 43.6% (186/425) of cases with diameter 15 cm or above. The mean pre-operative CA125 value was 320.89 IU/mL (3.7–8831 IU/mL), with 72.1% (307/427) of cases higher than 35 IU/mL. Ascites was present in 23.4% (100/427) of cases. USG scores were 1, 0, and 3 in 7.5% (32/427), 41.9% (179/427), and 50.6% (216/427) of cases, respectively. For MRI score, 52% (221/425) of the tumors scored greater than 25, while only 15.5% (66/427) scored less than 25. Almost 94.8% (405/427) of cases had laparotomies, and 97.7% (417/427) of cases were elective operations. Concerning tumor integrity, 61.8% (264/427) of the tumors were ruptured during manipulation. The majority of cases had either one or two blocks prepared during frozen section, with only 7.0% (30/427) of cases having three or more blocks. Imprints were not a common practice, and were done in only 15.9% (68/427) of cases.

Table 4 shows the association of clinicopathological parameters with underdiagnoses using logistic regression analysis. Of the total 425 cases, 355 were in the correct diagnosis group and 70 were in the underdiagnosis group. At univariate regression analysis, presence of intact capsule was positively associated with underdiagnosis (unadjusted OR (OR unadj)=1.9, 95% CI 1.13 to 3.19). Compared to other histologic types, the odds of underdiagnosis in serous and clear cell lesions were lower (OR unadj=0.33, 95% CI 0.12 to 0.88 and OR unadj=0.41, 95% CI 0.17 to 0.97, respectively), while mucinous lesions did not show significant difference. Stage I lesions were positively associated with underdiagnosis when compared with higher-stage lesions (OR unadj=3.76, 95% CI 1.57 to 9.01). A USG score of 0 was also positively associated with underdiagnosis (OR unadj=2.52, 95% CI 1.14 to 5.59). At multivariate analysis, only staging and USG score were positively associated with underdiagnosis, where the adjusted OR for stage I lesions was 3.62 (95% CI 1.50 to 8.69), and that for a USG score of 0 was 2.32 (95% CI 1.03 to 5.21).

We further reviewed how underdiagnoses would affect the completeness of staging operation. Although there were 70 cases of underdiagnoses, as surgical staging is not required if the ovarian tumor is metastatic in nature, we excluded the seven cases with a final diagnosis of metastatic malignant tumors. For the remaining 63 underdiagnosed cases, complete surgical staging was performed in 29/63 (46%) cases, while 54.0% (34/63) of cases were considered as incomplete staging. Among the 29 optimally staged cases, 62% (18/29) were malignant cases and 38% (11/29) were borderline cases. For the 34 incompletely staged cases, 82% (28/34) cases were malignant while borderline tumor only accounted for 18% (6/34) of cases.

**Discussion**

In the current study, among the 1143 cases with IFS of ovarian lesions, there were 133 borderline tumors and 294 malignant tumors. Apart from a slightly higher prevalence of borderline tumors in our hospital, our series showed a similar distribution to the recent Cochrane systematic review. In that systematic review, borderline and malignant tumors were considered test-positive and benign lesions test-negative, the average IFS sensitivity was 96.5% and specificity was 89.5%. In our study, if combining both borderline and malignant tumors as single positive group similarly, the IFS sensitivity was 92.51% (95% CI 89.61% to 94.64%) and the specificity was 100% (95% CI 99.47% to 100%). A more conservative approach in pathology reporting of IFS could attribute to a slightly lower sensitivity but excellent specificity. A recent retrospective review of 277 cases in a large Australian teaching hospital concluded the overall IFS sensitivity for diagnosing malignant disease was 75.9% and specificity was 100%. Diagnostic values of IFS were also calculated for individual tumor groups. It is interesting to note that the PPV of a borderline IFS diagnosis was only 75.32%. In this study, we adopted a stringent approach; tumors with frozen diagnosis “at least borderline tumor” would be classified as borderline. As expected a significant portion of such cases would be malignant tumors in the final diagnosis. Similarly, the sensitivity of IFS in diagnosing malignant tumors was only 81.29% because of the same reason.

Previous studies found that IFS performed less well in differentiating borderline and malignant tumors. In the current study, 24.7% of borderline tumors at IFS were upgraded to malignant tumors at final diagnosis. The figure was similar to the reported average upgrade rate of 21%. Diagnoses were considered concordant when the IFS diagnosis was borderline or at least borderline with final malignant pathology, as these cases were managed in a similar way intra-operatively.

There are different types of errors affecting the accuracy of IFS diagnosis, including sampling errors, technical errors, and interpretation errors as mentioned by Stewart et al. On reviewing the IFS slides and final paraffin slices of the 70 underdiagnosed cases, sampling errors were noted in 47% (33/70) of cases. As expected, in tumors notoriously known to be heterogeneous in nature, such as mucinous tumors and teratomas, sampling was particularly problematic. Interpretation errors were noted in 6/70 cases (8.6%), the most common scenario was that the atypical cells were not recognized in the first viewing of the IFS slides, but could be appreciated on second review coupled with converted paraffin slides. In general, the preparation of the cryostat slides was considered quite satisfactory. Technical errors were only noted in two cases (2.9%), in which there was under-exposing of tissue in the IFS slides. No obvious errors were found in the remaining 31 underdiagnosed cases. For the two overdiagnosed cases, interpretation errors were regarded as the main contributing factor.
Table 3  Subjects’ clinicopathological characteristics and the accuracy of frozen section diagnoses (N=427)*

| Characteristic            | Correct diagnosis (n=355) | Underdiagnosis (n=70) | Overdiagnosis (n=2) | P values† | All (N=427) |
|---------------------------|---------------------------|-----------------------|---------------------|-----------|-------------|
| **Age (years)**           |                           |                       |                     |           |             |
| <40                       | 74 (20.8)                 | 13 (18.6)             | 1                   | 0.667     | 88 (20.6)   |
| ≥40                       | 281 (79.2)                | 57 (81.4)             | 1                   |           | 339 (79.4)  |
| **Menopausal status**     |                           |                       |                     | 0.25      |             |
| Pre-menopausal            | 194 (54.6)                | 33 (47.1)             | 2                   |           | 229 (53.6)  |
| Post-menopausal           | 161 (45.4)                | 37 (52.9)             | 0                   |           | 198 (46.4)  |
| **Histology type**        |                           |                       |                     | 0.052     |             |
| Germ cell lesions         | 20 (5.6)                  | 6 (8.6)               | 0                   |           | 26 (6.1)    |
| Sex cord-stromal lesions  | 11 (3.1)                  | 4 (5.7)               | 0                   |           | 15 (3.5)    |
| Metastatic lesions        | 20 (5.6)                  | 7 (10)                | 0                   |           | 27 (6.3)    |
| Serous lesions            | 61 (17.2)                 | 5 (7.1)               | 1                   |           | 67 (15.7)   |
| Mucinous lesions          | 97 (27.3)                 | 26 (37.1)             | 1                   |           | 124 (29.0)  |
| Endometrioid lesions      | 60 (16.9)                 | 13 (18.6)             | 0                   |           | 73 (17.1)   |
| Clear cell lesions        | 69 (19.4)                 | 7 (10)                | 0                   |           | 76 (17.8)   |
| Unclassified              | 17 (4.8)                  | 2 (2.9)               | 0                   |           | 19 (4.4)    |
| **Staging**               |                           |                       |                     | 0.01      |             |
| I                         | 240 (67.6)                | 57 (81.4)             | 2                   |           | 299 (70.0)  |
| II                        | 34 (9.6)                  | 1 (1.4)               | 0                   |           | 35 (8.2)    |
| III                       | 59 (16.6)                 | 5 (7.1)               | 0                   |           | 64 (15.0)   |
| IV                        | 2 (0.6)                   | 0 (0)                 | 0                   |           | 2 (0.5)     |
| Unstaged                  | 20 (5.6)                  | 7 (10)                | 0                   |           | 27 (6.3)    |
| **Capsule intact**        |                           |                       |                     | 0.014     |             |
| Intact                    | 127 (35.8)                | 36 (51.4)             | 0                   |           | 163 (38.2)  |
| Ruptured                  | 228 (64.2)                | 34 (48.6)             | 2                   |           | 264 (61.8)  |
| **Frozen section blocks (n)** |                         |                       |                     | 0.504     |             |
| 1                         | 141 (39.7)                | 28 (40)               | 1                   |           | 170 (39.8)  |
| 2                         | 191 (53.8)                | 35 (50)               | 1                   |           | 227 (53.2)  |
| ≥3                        | 23 (6.5)                  | 7 (10)                | 0                   |           | 30 (7.0)    |
| **Imprints**              |                           |                       |                     | 0.669     |             |
| Yes                       | 58 (16.3)                 | 10 (14.3)             | 0                   |           | 68 (15.9)   |
| No                        | 297 (83.7)                | 60 (85.7)             | 2                   |           | 359 (84.1)  |
| **Tumor size (cm)**       |                           |                       |                     | 0.201     |             |
| <5                        | 9 (2.5)                   | 3 (4.3)               | 0                   |           | 12 (2.8)    |
| 5–14.9                    | 197 (55.5)                | 31 (44.3)             | 1                   |           | 228 (53.6)  |
| ≥15                       | 149 (42.0)                | 36 (51.4)             | 1                   |           | 186 (43.6)  |
| **Tumor location**        |                           |                       |                     | 0.773     |             |
| Bilateral                 | 45 (12.7)                 | 8 (11.4)              | 0                   |           | 53 (12.4)   |
| Unilateral                | 310                       | 62 (88.6)             | 2                   |           | 374 (87.6)  |
| **Ascites**               |                           |                       |                     | 0.446     |             |
| Yes                       | 86 (24.2)                 | 14 (20.0)             | 0                   |           | 100 (23.4)  |
| No                        | 269 (75.8)                | 56 (80.0)             | 2                   |           | 327 (76.6)  |
| **Ultrasound score**      |                           |                       |                     | 0.062     |             |
| 0                         | 22 (6.2)                  | 10 (14.3)             | 0                   |           | 32 (7.5)    |
| 1                         | 151 (42.5)                | 26 (37.1)             | 2                   |           | 179 (41.9)  |

Continued
At univariate logistic regression analysis, stage I lesion, intact capsule, and a USG score of 0 were positively associated with underdiagnosis. At multivariate logistic regression analysis, stage I tumor and a USG score of 0 remained as significant factors positively associated with IFS underdiagnosis. Owing to time constraints, when performing IFS, the attending pathologist can only select the most suspicious areas for cryostat slides, most commonly looking for solid areas. For those ovarian tumors with USG score zero, probably no obvious solid area could be found during gross examination. The attending pathologist could only take random sectioning from the cyst wall, thus increasing the chance of sampling errors. Conversely, for stage 2 lesions or above, it is common to have outer surface irregular growth, or presence of raw areas owing to excision of tumor with invasion to adjacent areas. All these can provide clues to the pathologist for selecting representative tissue during IFS. This may explain why accuracy was jeopardized in stage I lesions. This suggests a paradoxical dilemma. IFS is most useful in grossly stage I early ovarian cancer. An accurate diagnosis can allow the surgeon to proceed to staging procedure appropriately, including lymphadenectomy, which may upstage the disease if occult spreads were present. With accurate surgical and pathological staging, 18% of grossly stage I ovarian cancer will be upgraded to FIGO stage 2 or higher. Thus extra care needs to be exercised in IFS interpretation in early-stage disease.

Some previous studies investigated factors affecting the accuracy of borderline tumors. Gultekin et al found that ovarian mass dimension, presence of solid component, preoperative CA125 value, and capsule integrity were factors affecting the accuracy of IFS. One study reported mucinous histology to be the only significant factor in IFS underdiagnosis. Ureyen et al also addressed the diagnostic difficulty for frozen analysis for borderline ovarian tumors, especially in mucinous and large tumors. In our multivariate logistic regression analysis we could not demonstrate any significant histology type accounting for underdiagnosis. However, in the univariate analysis we noted that tumors of serous and clear cell histology were negatively associated with underdiagnosis, implying that the performance of IFS in these two histological subtypes were probably superior. Indeed, if using mucinous lesion as a separate variable, statistically significant association with underdiagnosis was found in univariate regression (unadjusted OR=1.94 (95% CI 1.14 to 3.29); p=0.014). This is in accordance with previous studies that showed mucinous tumors impose greater challenges to pathologists when performing IFS. Tangjitgamol et al commented that most cases of incorrect diagnoses were the low malignant potential mucinous tumors, which were usually large and had heterogenic histology. During IFS, when the diagnosis is solely by microscope, it is not easy to differentiate whether an mucinous tumor is of primary ovarian origin or metastasis. We know that even with the help of further immunohistochemical profiling, sometimes it can still be challenging.

With a large and heterogeneous tumor, the attending pathologist may have difficulty in selecting adequate and representative areas for examination, especially when there are time constraints. Thus, in our hospital, sometimes we may encounter IFS diagnosis being “at least borderline tumor”, of even “focal atypia noted, cannot exclude borderline tumor or malignancy”. At this juncture, the surgeons need to communicate clearly with the pathologist and consider other information before proceeding to further appropriate procedures, including the pre-operative imaging finding and the intra-operative plan verified by the previously signed informed consent.

We further reviewed how underdiagnoses would affect the completeness of a staging operation. For the 63 underdiagnosed...
Table 4 Association of clinicopathological characteristics with underdiagnosis: logistic regression analyzes

| Characteristic                        | Univariate | Multivariate* |
|---------------------------------------|------------|---------------|
|                                       | Unadj (95% CI) | P value | Adj (95% CI) | P value |
| Age≥40 years                          | 1.15 (0.60 to 2.22) | 0.667 | 3.62 (1.50 to 8.69) | 0.004 |
| Post-menopausal                       | 1.35 (0.81 to 2.26) | 0.251 | | |
| Histology type (ref: others)          |            |    |            | |
| Serous lesions                        | 0.33 (0.12 to 0.88) | 0.027 | | |
| Mucinous lesions                      | 1.07 (0.60 to 1.92) | 0.814 | | |
| Clear cell lesions                    | 0.41 (0.17 to 0.97) | 0.042 | | |
| Staging (ref: II–IV)                  |            |    |            | |
| I                                     | 3.76 (1.57 to 9.01) | 0.003 | | |
| Intact capsule                        | 1.90 (1.13 to 3.19) | 0.015 | | |
| Frozen section blocks (n) (ref: 1)    |            |    |            | |
| 2                                     | 0.92 (0.54 to 1.59) | 0.772 | | |
| ≥3                                    | 1.53 (0.60 to 3.92) | 0.372 | | |
| Imprints                              | 0.85 (0.41 to 1.76) | 0.669 | | |
| Tumor size (cm; ref: <5)              |            |    |            | |
| 5–14.9                                | 0.47 (0.12 to 1.84) | 0.280 | | |
| ≥15                                   | 0.72 (0.19 to 2.81) | 0.642 | | |
| Bilateral tumor                       | 0.89 (0.40 to 1.98) | 0.773 | | |
| Ascites                               | 0.78 (0.41 to 1.47) | 0.447 | | |
| Ultrasound score 0 (ref: ≥1)          | 2.52 (1.14 to 5.59) | 0.023 | 2.32 (1.03 to 5.21) | 0.041 |
| Pre-operative CA125 >35 IU/mL         | 0.68 (0.39 to 1.17) | 0.165 | | |
| Risk of Malignancy Index (RMI) (ref: <25) | | | | |
| 25–250                                | 0.57 (0.27 to 1.17) | 0.126 | | |
| >250                                  | 0.53 (0.27 to 1.05) | 0.067 | | |
| Open surgery                          | 4.34 (0.57 to 32.79) | 0.155 | | |
| Scheduled elective surgery            | 1.79 (0.22 to 14.40) | 0.582 | | |

*Multivariate logistic regression using backward selection method with variables including histology type, staging, capsule intact, ultrasound score, and RMI.

OR_adj, adjusted OR; OR_unadj, unadjusted OR; ref, reference.

cases evaluated, 54.0% (34/63) of operations were considered as incomplete staging. This figure was similar to that of a recent Australian study. However, only 23.5% (8/34) of these incompletely staged cases underwent a second staging operation. In the majority of these eight cases, the primary procedures were either unilateral ovarian cystectomy or unilateral salpingo-oophorectomy, and second staging laparotomies were more strongly indicated. The remaining cases were mainly upstaged to malignant tumors finally with borderline as IFS diagnosis. They were regarded as incompletely staged as lacking systematic lymphadenectomy. Not uncommonly, patients would be reluctant to undergo a second major operation only for an additional lymphadenectomy, especially if pre-operative imaging or intra-operative gross findings showed no evidence of enlarged lymph nodes. Also, a patient’s premorbid status is also important when considering the feasibility of a second operation. Conversely, in some cases adjuvant chemotherapies were indicated anyway such as high-grade tumors or stage IC disease, so patients would proceed directly to chemotherapy. The two overdiagnosed cases were borderline tumors with malignant frozen diagnosis. There was no over treatment in both cases as staging laparotomy including systematic lymphadenectomy was still an appropriate procedure for borderline ovarian tumor.

The main limitation of this study was the heterogeneous nature of the cases. All ovarian masses sent for IFS during the 11-year study period were included, from non-neoplastic benign lesions to frank malignancy. Conversely, this allowed a sufficient pool of cases, taking into account the fact that this cohort was retrieved from a single center. Similarly, it would be difficult to have a designated team of personnel, both in the theater or laboratory, to handle all the cases. Most malignant cases would be treated by the gynecological oncologists. General gynecologists would treat cases with no or low suspicion, with involvement of gynecological oncologists for subsequent staging procedures. IFS was performed by on-duty specialist pathologists. Individual pathologist performance and changes in reporting protocols over time are potential confounding factors. Nevertheless, this series included a large number of cases, and the case distribution in this study was comparable to that of a recent systematic review.
The diagnostic criteria of borderline ovarian tumors have generated many challenges and controversies for pathologists. The latest terminology and diagnostic criteria were implemented following the 2014 WHO Classification of Tumors of the Female Reproductive Organs. Morton et al regarded ovarian tumors with micro-invasion or intra-epithelial carcinoma as malignant for analysis, which may result in a lower sensitivity for diagnosing malignancy. In our study, we included borderline tumors associated with micro-invasion or intra-epithelial carcinoma in the borderline group, in line with the latest WHO classification.

Our study has demonstrated a high level of accuracy of IFS, especially in differentiating borderline or malignant tumors from benign lesions. Frozen sections should always be interpreted with caution, especially in early-stage ovarian malignancy. Ultimately, the management plan should be well formulated by pre-operative workup, from basic history-taking and physical examination, to serum tumor markers and detailed imaging. Ultrasonography should ideally be performed by experienced operators, coupled with further imaging such as computed tomography and magnetic resonance imaging if indicated. Thorough pre-operative patient counseling and informed consent are mandatory for every case, so that the attending surgeon can proceed in accordance with the different intra-operative findings and IFS reporting. Finally, intra-operative communication between surgeons and attending pathologists is of utmost importance, so that information is accurately shared by both parties to minimize interpretation errors.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Ethics approval** This study was approved by the Kowloon West Cluster Clinical Research Ethics Committee (KWC-CREC), with KWC-CREC reference: KW/EX-15-211(94-07).

**Provenance and peer review** Not commissioned, externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0

**REFERENCES**

1. Gal AA, Cagle PT. The 100-year anniversary of the description of the frozen section procedure. JAMA 2005;294:3135–7.
2. Meys EMJ, Jeeleof LS, Achten NMJ, et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound Obstet Gynecol 2017;49:784–92.
3. Ratnavelu ND, Brown AP, Mallett S, et al. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev 2016;3:CD010360.
4. Medeiros LR, Rosa DD, Edelweiss MI, et al. Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J Gynecol Cancer 2005;15:192–202.
5. Ganesan R, Brown LJ, Kehoe S, et al. The role of frozen sections in gynaecological oncology: survey of practice in the United Kingdom. Int J Obstet Gynaecol 2005;15:192–202.
6. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;142:1–5.
7. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922–9.
8. Morgan RJ, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1. 2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016;14:1134–83.
9. Morton R, Anderson L, Carter J, et al. Intraoperative frozen section of ovarian tumors: a 6-year review of performance and potential pitfalls in an Australian Tertiary Referral Center. Int J Gynecol Cancer 2017;27:17–21.
10. Ureyen I, Turan T, Cirik DA, et al. Frozen section in borderline ovarian tumors: is it reliable? Eur J Obstet Gynecol Reprod Biol 2014;181:115–8.
11. Stewart CJ, Brennan BA, Hammond IG, et al. Intraoperative assessment of ovarian tumors: a 5-year review with assessment of discrepant diagnostic cases. Int J Gynecol Pathol 2006;25:216–22.
12. Cross PA, Naik R, Patel A, et al. Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience. BJOG 2012;119:194–201.
13. Maggioni A, Benucci R, Dell’Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006;95:699–704.
14. Gultekin E, Gultekin OE, Cingilioglu B, et al. The value of frozen section analysis in the diagnosis of borderline ovarian tumors. J Cancer Res Ther 2011;7:416–21.
15. Song T, Choi CH, Kim HJ, et al. Accuracy of frozen section diagnosis of borderline ovarian tumors. Gynecol Oncol 2011;122:127–31.
16. Tangiyamal S, Jesadapratarkul S, Manusirivithaya S, et al. Accuracy of frozen section in diagnosis of ovarian mass. Int J Gynecol Cancer 2004;14:212–9.
17. Hauptmann S, Friedrich K, Redline R, et al. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 2017;470:125–42.
18. Kurman RJ. WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer, 2014.